uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead
Dec. 16, 2025 — uniQure N.V. (NASDAQ: QURE) is back in the spotlight Tuesday after a notable extended-hours rebound. The gene therapy developer’s shares were highlighted among top pre-market gainers, rising about 15% to roughly $23.50 in early trading, following a strong after-hours move the prior session. StockAnalysis+1 The snapback comes at a time when the fundamental narrative around uniQure remains dominated by one big question: how (and when) the U.S. FDA will allow AMT-130—uniQure’s Huntington’s disease gene therapy—to move toward a Biologics License Application (BLA) after the agency signaled the current evidence package is not sufficient as “primary” support
